EU generics group welcomes new “counterfeit” definition
This article was originally published in SRA
Executive Summary
Greg Perry, director general of the European Generic medicines Association (EGA), has welcomed the new definition of a “counterfeit” medicine adopted at the third general meeting of the World Health Organization’s anticounterfeiting task force, IMPACT. The new definition puts an end to any confusion over allegedly patent-infringing products, “which have nothing to do with counterfeiting or public health”, Mr Perry said1.